CYP2C19 Phenotype, P2Y12 Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy

CYP2C19 Phenotype, P2Y12 Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy

Background Use of CYP2C19 genotyping to guide antiplatelet therapy is associated with improved clinical outcomes in patients naïve to P2Y12 inhibitors undergoing percutaneous coronary intervention. The relationship between CYP2C19 genotype and clinical outcomes in patients on maintenance clopidogrel...

Full description

Saved in:
Bibliographic Details
Main Authors: Rajiv C. Patel, Cameron D. Thomas, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Amber L. Beitelshees, Julio D. Duarte, Luis Ortega‐Paz, Natasha Kulick, Marshall Winget, Anh B. Nguyen, William E. Yang, Sanjay Venkatesh, Dominick J. Angiolillo, Larisa H. Cavallari, Craig R. Lee, George A. Stouffer
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
ACS
clopidogrel
genotyping
MACE
PCI
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.125.041634
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.125.041634

Similar Items